74808-00-7

Upstream product

• 143327-79-1 ((S)-1-benzyl-2-prop-2-ynyl)carbamic acid t-butyl ester 
• 1133051-90-7 1-benzylprop-2-yn-1-yl pivalate 
• 1310480-50-2 (S)-N-(1-phenylbut-3-yn-2-yl)-2-methoxybenzenamine 
• 135663-97-7 1-phenylbut-3-yn-2-ol 
• 122-78-1 phenylacetaldehyde 
• 289894-92-4 1-phenylbut-3-yn-2-yl acetate 
• 100841-19-8 (S)-(-)-3-Phenyl-2-triphenylmethylamino-1-propanol 
• 3182-95-4 L-Phenylalaninol 
• 63-91-2 L-phenylalanine 
• 176962-18-8 tert-butyl [(1S)-1-benzyl-3,3-dibromoprop-2-en-1-yl]carbamate 
• 72155-45-4 Boc-L-phenylalaninal 
• 74807-93-5 (2S)-N-(1-Benzyl-3-trimethylsilyl-2-propynyl)-2-methoxymethyl-1-pyrrolidinemethanimine 

Downstream Products

• 1012049-25-0 C₅₀H₇₅N₁₁O₁₂S 
• 1242276-48-7 C₁₉H₂₆N₂O₃ 
• 143327-79-1 ((S)-1-benzyl-2-prop-2-ynyl)carbamic acid t-butyl ester 
• 1310480-42-2 (S)-tert-butyl 2-benzyl-2,5-dihydro-1H-pyrrole-1-carboxylate 
• 1229653-77-3 C₂₀H₂₆N₂O₃ 
• 890139-54-5 2-allyl 3,4-dimethyl 5-((S)-3-(3-((R)-1-phenylbut-3-yn-2-yl)ureido)-4-(triisopropylsilyloxy)butyl)furan-2,3,4-tricarboxylate 
• 890139-56-7 2-allyl 3,4-dimethyl 5-((S)-3-(3-((S)-1-phenylbut-3-yn-2-yl)ureido)-4-(triisopropylsilyloxy)butyl)furan-2,3,4-tricarboxylate 

Relevant academic research and scientific papers

Peptidotriazolamers Inhibit Aβ(1–42) Oligomerization and Cross a Blood-Brain-Barrier Model

In peptidotriazolamers every second peptide bond is replaced by a 1H-1,2,3-triazole. Such foldamers are expected to bridge the gap in molecular weight between small-molecule drugs and protein-based drugs. Amyloid β (Aβ) aggregates play an important role in Alzheimer's disease. We studied the impact of amide bond replacements by 1,4-disubstituted 1H-1,2,3-triazoles on the inhibitory activity of the aggregation “hot spots” K16LVFF20 and G39VVIA42 in Aβ(1–42). We found that peptidotriazolamers act as modulators of the Aβ(1–42) oligomerization. Some peptidotriazolamers are able to interfere with the formation of toxic early Aβ oligomers, depending on the position of the triazoles, which is also supported by computational studies. Preliminary in vitro results demonstrate that a highly active peptidotriazolamer is also able to cross the blood-brain-barrier.

Enantioselective copper-catalysed propargylic substitution: Synthetic scope study and application in formal total syntheses of (+)-anisomycin and (-)-cytoxazone

A copper catalyst with a chiral pyridine-2,6-bisoxazoline (pybox) ligand was used to convert a variety of propargylic esters with different side chains (R=Ar, Bn, alkyl) into their amine counterparts in very high yields and with good enantioselectivities (up to 90% enantiomeric excess (ee)). Different amine nucleophiles were applied in the reactions and the highest enantioselectivities were obtained for aniline and its analogues. Interestingly, some carbon nucleophiles could also be used and with indoles excellent ee values were obtained (up to 98% ee). The versatility of the propargylic amines obtained was demonstrated by their further elaboration to formal total syntheses of the antibiotic (+)-anisomycin and the cytokine modulator (-)-cytoxazone. Copyright

Histone deacetylase inhibitors: Synthesis of cyclic tetrapeptides and their triazole analogs

Synthesis of nine macrocyclic peptide HDAC inhibitors and three triazole derivatives is described. HDAC inhibitory activity of these compounds against HeLa cell lysate is evaluated. The biological data demonstrate that incorporation of a triazole unit improves the HDAC inhibitory activity.

A new stereoselective synthesis of chiral γ-functionalized (E)-allylic amines

Chiral t-Boc protected propargylic amines have been obtained starting from aminoaldehydes derived from natural aminoacids. Stannylcupration of these substrates affords an easy regio- and stereocontrolled route to the corresponding γ-stannylated (E)-allylamines which are useful intermediates for the synthesis of the corresponding γ-functionalized allylic systems.